Abstract
Cervical cancer is the fourth most common cancer in females. Clear cell adenocarcinoma of the cervix is an uncommon histological variant and is usually seen with intrauterine exposure to diethylstilbestrol. A 28-year-old female with no intrauterine exposure to diethylstilbestrol presented with postcoital bleeding. A pelvic exam revealed a cervical mass. Imaging confirmed the cervical mass and positron emission tomography scan showed an increased uptake in the cervical mass as well as the para-aortic and pelvic lymph nodes. Biopsy showed a clear cell carcinoma of the cervix. She was treated with cisplatin and paclitaxel for eight cycles and concurrent radiation therapy. She had a complete response to therapy and has been in complete remission nine months from the end of therapy. There are no clear guidelines for the treatment of clear cell carcinoma with current therapy based on the treatment of squamous and non-clear cell adenocarcinoma. Cisplatin and paclitaxel could be an option, given the successful treatment of the patient in our case.
Highlights
Cervical cancer poses a significant toll on the global cancer scene, being the fourth most common cancer in females
Cervical tumors arising from the ectocervix are most commonly squamous cell carcinomas and those arising from the endocervix are commonly adenocarcinomas
We present a patient with cell adenocarcinoma of the cervix (CCAC) who presented with postcoital bleeding and successfully completed treatment with weekly cisplatin and paclitaxel in combination with radiation therapy
Summary
Cervical cancer poses a significant toll on the global cancer scene, being the fourth most common cancer in females. There have been reported cases of clear cell carcinoma of the cervix without any identifiable exposure to DES. The patient was diagnosed with FIGO stage IB2 (T1b2N1M0) clear cell carcinoma of the cervix. She was treated with cisplatin at a dose of 30 mg/m2 and paclitaxel at a dose of 50 mg/m2 for a total of eight cycles. She received a total dose of 5,580 centigray (cGY) of radiation She underwent an MRI to assess treatment and she was found to have resolution of the cervical mass and the para-aortic and pelvic lymph nodes (Figure 4). The patient continues to follow with oncology and has had a complete response to treatment and is currently nine months from the end of the combined therapy with no recurrence noted
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
